Within-host evolution of SARS-CoV-2: how often arede novomutations transmitted?

Abstract

Despite a relatively low mutation rate, the large number of SARS-CoV-2 infections has allowed for substantial genetic change, leading to a multitude of emerging variants. Using a recently determined mutation rate (per site replication), as well as parameter estimates for within-host SARS-CoV-2 infection, we apply a stochastic transmission-bottleneck model to describe the survival probability of de novo SARS-CoV-2 mutations. For narrow bottlenecks, we find mutations affecting per-target-cell attachment rate (with phenotypes associated with fusogenicity and ACE2 binding), have similar transmission probabilities to mutations affecting viral load clearance (with phenotypes associated with humoral evasion). We further find that mutations affecting the eclipse rate (with phenotypes associated with reorganization of cellular metabolic processes and synthesis of viral budding precursor material) are highly favoured relative to all other traits examined. We find mutations leading to reduced removal rates of infected cells (with phenotypes associated with innate immune evasion) have limited transmission advantage relative to mutations leading to humoral evasion. Predicted transmission probabilities, however, for mutations affecting innate immune evasion are more consistent with the range of clinically-estimated household transmission probabilities for de novo mutations. This result suggests that although mutations affecting humoral evasion are more easily transmitted when they occur, mutations affecting innate immune evasion may occur more readily. We examine our predictions in the context of a number of previously characterized mutations in circulating strains of SARS-CoV-2. Our work offers both a null model for SARS-CoV-2 substitution rates and predicts which aspects of viral life history are most likely to successfully evolve, despite low mutation rates and repeated transmission bottlenecks.

SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series

“…Modelling has also been used to determine how vaccine-driven IgG counts decay as a function of age, prior infection, T-cell response, and dosing intervals 29 . Modelling has also been used to relate infection outcome severity by cytokine measures 30 and to understand key within-host characteristics of infection 31 and evolutionary dynamics 32 . In this work, we employed a simple exponential approach to assess immune waning decay kinetics.…”